You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

Oct 08, 2021

Evive Biotech’s Ryzneuta™ Marketing Authorization Application Accepted for Review by European Medicines Agency

October 8, 2021, Singapore – Evive Biotech, a global biologics company developing novel biologic therapies, announces Company’s Marketing Authorization Application (MAA) for Ryzneuta™ for treatment of chemotherapy-induces neutropenia (CIN) in cancer patients after chemotherapy has been accepted and is now under EMA’s centralized review.

The application will be reviewed by the EMA’s Committee for Medicinal Products for Human Use (CHMP) under the centralized procedure for all 27 Member States of the European Union, as well as Norway, Iceland, and Liechtenstein. The MAA is supported by data from three pivotal phase III trials. All three trials met their primary and secondary endpoints, demonstrating desirable efficacy and safety profile of Ryzneuta™.

“EMA acceptance for review of Evive’s MAA marks another significant milestone for our clinical and commercial teams,” said Dr. Jubo Liu, Evive Biotech’s CEO. “The EU is an important region for the global commercialization of Ryzneuta™, where we look forward to working with regulatory authorities to bring this novel biologic therapy to CIN patients in the EU and beyond.”

In addition to the MAA submission to EMA and Biologics License Application (BLA) submission to the FDA earlier this year with a PDUFA goal date of March 30, 2022, Evive is also working towards submitting a New Drug Application (NDA) to China’s National Medical Products Administration.

***ENDS***

About Ryzneuta™

Ryzneuta™ (efbemalenograstim alfa) is developed for the treatment of chemotherapy-induces neutropenia (CIN) in cancer patients after chemotherapy. Neutropenia is a common side-effect of chemotherapy and is a condition characterized by low levels of neutrophils, a type of white blood cell that fights infection. Ryzneuta™ is a recombinant fusion protein containing G-CSF at the amino terminal and human IgG2-Fc fragment at the carboxyl terminal. Ryzneuta™ is expressed in Chinese Hamster Ovary (CHO) cells. Ryzneuta™ exists as a homodimer with two G-CSF-Fc molecules covalently linked through disulfide bonds formed between the Fc moiety of the molecule. Through specific binding to its receptor, G-CSF receptor, Ryzneuta™ stimulates survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils. Ryzneuta™ strengthens the immune system’s ability to fight infection by increasing the production of neutrophils, preventing potential chemotherapy dose reductions and delays that may compromise treatment outcomes. The three Ryzneuta™ pivotal trials are all multi-center, randomized, multi-dose, active-controlled study comparing the efficacy and safety of Ryzneuta™.

About Evive Biotech

Evive Biotech is a global biologics company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, Singapore, and China. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, Evive adopts a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global market quickly and efficiently to address unmet medical needs, making a real and lasting difference to patients and their families worldwide.

To learn more about Evive Biotech, visit www.evivebiotech.com.

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

X
Share to WeChat